Deelnemers

Heb je een vraag? Neem gerust contact met ons op.

 

Telefoon: 050 - 36 11 113 (werkdagen van 8.00 - 17.00 uur)

Contactformulier

Researchers

Do you have a question regarding working with Lifelines? Please contact us, we're happy to help you.

Contact us

Pers

We voorzien media graag van informatie en we behandelen graag verzoeken voor interviews, opnames en beeldmateriaal.

Stuur een e-mail

Contact

Unravelling the dark matter of infectious diseases, environmental and genetic factors tipping the balance towards NCDs. Proposal acronym: ID-DarkMatter-NCD

Immune-related noncommunicable diseases (IR-NCDs) could potentially be triggered by no such several identified infectious disease (ID). These infectious microbes have large genomes encoding many antigens possibly associated with IR-NCDs representing the dark matter of ID-immune interactions. Furthermore, exposure to an ID alone typically does not trigger development of an IR-NCD. Genetic and environmental aspects also affect the onset of IR-NCDs, but the exact factors are unknown for most IR-NCDs. Here, we aim to 1.) identify IDs triggering IR-NCDs by screening for antibody responses against 600,000 ID antigens, and 2.) to disentangle environmental and genetic factors affecting the transition from IDs to IR-NCDs. We will combine novel multi-omics approaches and technologies for personalized genotyping of HLA and adaptive immune receptor genes to deeply profile 6,000 patients of six IR-NCDs (PCC, multiple sclerosis, ME/CFS, rheumatoid arthritis, lupus, IBD) to identify novel biomarkers and disease mechanisms. This project will represent the largest and most deeply profiled systematic study of multiple IR-NCDs with layered datasets allowing for comparative analyses yielding insights into shared mechanisms and potential differences in the role of IDs between IR-NCDs. Building on associations identified from population scale and clinical cohorts, we will demonstrate causality in gnotobiotic mouse models, and leverage machine learning (ML) algorithms to predict disease progression and response to treatment. The combination of novel assays with ML represents a broadly applicable pipeline that can be used for studying the interplay of any other IDs/ IR-NCDs

Year of approval

2024

Institute

Vall Hebron Hospital Research Institute

Primary applicant

JuliĆ , A.